GSA CAPITAL PARTNERS LLP

Position in ATYR — aTYR PHARMA INC

CIK 1362033 LONDON, X0

Position in ATYR

as of Jun 30, 2026 · filed Aug 6, 2026 Compact

Position Value

$2,062,553

+$748,576 QoQ

Shares Held

3,454,863

+105.1% QoQ

Ownership

3.52%

of shares outstanding

% of Portfolio

0.14%

of 13F equity value

Holder Rank

of 90 holders

Holding Since

Dec 2021

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. ATYR ranks #7 (2.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IOVA	Iovance Biotherapeutics, Inc.	655,318	$2,726,122
2	IMVT	Immunovant, Inc.	65,267	$2,514,737
3	GOSS	Gossamer Bio, Inc.	14,986,947	$2,472,846
4	AXSM	Axsome Therapeutics, Inc.	9,419	$2,305,488
5	CABA	Cabaletta Bio, Inc.	668,563	$2,079,230
6	MLTX	MoonLake Immunotherapeutics	106,695	$2,077,351
7	ATYR	aTYR PHARMA INC This page	3,454,863	$2,062,553
8	CORT	Corcept Therapeutics Inc	23,257	$2,022,196

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,062,553	3,454,863	+105.1%	Shares	Sole	2026-08-06
2026-03-31	$1,313,977	1,684,586	-36.0%	Shares	Sole	2026-05-08
2025-12-31	$2,059,789	2,630,638	+272.2%	Shares	Sole	2026-02-06
2025-09-30	$509,553	706,731	+42.4%	Shares	Sole	2025-11-07
2025-06-30	$2,516,185	496,289	+49.3%	Shares	Sole	2025-07-22
2025-03-31	$1,003,618	332,324	+21.1%	Shares	Sole	2025-05-08
2024-12-31	$993,422	274,426	-4.2%	Shares	Sole	2025-02-07
2024-09-30	$504,416	286,600	-11.1%	Shares	Sole	2024-11-05
2024-06-30	$503,037	322,460	+43.9%	Shares	Sole	2024-08-15
2024-03-31	$437,086	224,147	+105.3%	Shares	Sole	2024-05-03
2023-12-31	$153,921	109,164	+296.1%	Shares	Sole	2024-02-16
2023-09-30	$43,543	27,559	-53.1%	Shares	Sole	2023-11-15
2021-12-31	$439,168	58,791	—	Shares	Sole	2022-02-14
No filing history on record for this holder in this stock.